# Superluminal Medicines Inc.

> Superluminal Medicines is a Boston biotechnology company combining protein-conformation modeling, generative chemistry, structural biology and laboratory testing to develop small-molecule drugs targeting GPCRs. Its Hyperloop platform supports a wholly owned pipeline led by an oral MC4R agonist for rare genetic and hypothalamic obesity, alongside a discovery collaboration with Eli Lilly.

- **Founded:** 2022
- **Headquarters:** Boston, United States
- **Founders:** Cony D’Cruz (Co-founder and Chief Executive Officer), Ajay Yekkirala (Co-founder and Chief Scientific Officer)
- **Products:** Hyperloop™ Platform, Target GPS™, Oral selective, biased MC4R agonist, Partnered GPCR discovery
- **Notable:** Announced $213 million across seed, Series A and Series B rounds., Secured the August 2025 Lilly discovery collaboration with a potential value up to $1.3 billion., Advanced an oral MC4R candidate into IND-enabling studies in 2025.

## Products & services

- **Hyperloop™ Platform** — Integrated computational and experimental discovery engine combining protein dynamics, virtual screening, generative molecule design, structural biology, lead optimization and ADMET profiling. Publicly named on the current website; launch date not disclosed.
- **Target GPS™** — Proprietary predictive methods for modeling ensembles of GPCR conformations, including receptors without experimental structures. Public launch date not disclosed.
- **Oral selective, biased MC4R agonist** — Wholly owned investigational small molecule for rare genetic forms of obesity and hypothalamic obesity; IND-enabling studies announced in July 2025 and first Phase 1 trial expected by the end of 2026.
- **Partnered GPCR discovery** — Discovery and optimization of small molecules for undisclosed cardiometabolic and obesity targets under the Lilly collaboration.

## Achievements

- Announced $213 million across seed, Series A and Series B rounds.
- Secured the August 2025 Lilly discovery collaboration with a potential value up to $1.3 billion.
- Advanced an oral MC4R candidate into IND-enabling studies in 2025.
- Superluminal-affiliated researchers coauthored an August 2025 Communications Chemistry paper reporting in vitro activity in eight of nine synthesized CDK2 molecules.
- Established a scientific advisory board in September 2024.

## Latest updates

- **2026-09** — Announced $60 million Series B led by BVF Partners; Phase 1 trial of lead MC4R candidate expected by end of 2026.
- **2025-08** — Announced Lilly GPCR collaboration and publication of a generative chemistry/active-learning study.
- **2025-07** — Announced IND-enabling studies for the oral MC4R agonist; PDF release dated July 22, though the website lists it under August.
- **2025-06** — Axcelead and Superluminal announced intended expansion of their discovery collaboration.

## Links

- Website: https://www.superluminalrx.com/
- LinkedIn: https://www.linkedin.com/company/superluminalrx/

---

Profile page: https://yespress.io/superluminal-medicines-inc
Published by YesPress — https://yespress.io
Last updated: 2026-10-05